Goldman Sachs Sets BioMarin Target 75% Above Current Price

The gene therapy company is expected to introduce hemophilia drug that is projected to generate revenue of $1.2 billion by 2024 Continue reading… …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.